För att läsa nyheter på svenska, klicka här.

LIF – the research-based pharmaceutical companies’ association – inaugurated their new premises at Sveavägen 63 in central Stockholm. Of course we were there.

LIF President Anders Blanck began the inauguration by presenting the new premises as the new meeting place for anyone who wants to discuss cooperation in the healthcare field, plus a selection of offices as well as large and small meeting rooms to rent. There will also be temporary workstations available for visitors – and LIF sincerely hope that many will take advantage of the stimulating environment that the new space can offer.

LIF already share these premises with several other organisations, such as IML, Leading Health Care, Swecare and Pharmaceutical Insurance with more to move in once the current two floors
become three.

A highlight of the inauguration was the presence of Agneta Karlsson, Swedish State Secretary.
On behalf of the Swedish government she expressed the ambition for Sweden to become world leaders in Life Science, and stressed the need for all key individuals on every possible level to cooperate in order to achieve this goal. Not surprisingly, all representatives agreed wholeheartedly!

Life Science-organisationer knyter samarbetsband

After which it was time for the State Secretary to cut the inaugural ribbon, however the ribbon was cut into several pieces for each representative and then tied back together again in order to symbolise unified ambition as well as cooperation.

/Tomas Andersson
Senior Researcher, Opticom

Source: Life Science-organisationer knyter samarbetsband

Download PDF

I den nyligen publicerade sjätte upplagan av Opticoms årliga branschstudie ligger fokus på framtiden. Här presenteras en aktuell trendspaning där 148 personer från 58 olika företag inom den svenska läkemedelsindustrin har tagit på sig siarhatten och försökt förutspå hur vårdsverige kommer se ut 2025. Kristallkulan visar på både positiv utveckling med minskade regionala skillnader i vårdkvalitet och på negativa förändringar där ojämlikhet i vårdresultat utifrån socioekonomiska parametrar ökar och upptaget av innovativa läkemedel förblir oförändrat lågt, eller till och med försämras ytterligare.

Pharma Industri – Trendspaning 2025

Download PDF

För att läsa nyheter på svenska, klicka här.

In the newly published sixth edition of Opticom’s annual industry study, the focus is on the future.

The report involved the participation of 148 representatives from 58 different companies in the Swedish pharmaceutical industry who have looked in the crystal ball and tried to predict what Swedish healthcare will look like in 2025. The results showed positive developments with reduced regional disparities in quality of care and negative changes where inequality in healthcare results based on socio-economic parameters increases. Lastly, the uptake of innovative medicines will continue to remain low, or decrease even further.

To read the report (in Swedish), click here.

Download PDF

Just before the turn of the millennium, in 1999, the consulting and research company Opticom carried out a survey of how senior representatives of what were at that time the major global pharmaceutical companies saw the future. How well does the companies’ vision coincide with the way things are now, 15 years later?

The report, Prescription for a healthy industry, also formed the basis for a series of articles in Svenska Dagbladet/Näringsliv written by Elisabeth Sandlund. The report was partly based on in-depth interviews with 34 senior executives at what were at that time the 20 largest pharmaceutical companies. Their analysis resulted in three main points:

  • There is still a large unsatisfied need for pharmaceuticals. There is no cure for two thirds of all illnesses. The world population is getting older. New research methods are being developed all the time and there will be substantial growth in DTC (direct-to-consumer sales).
  • Quick access to market is a key to success. In the face of tougher future competition, companies must launch new innovative products quickly.
  • Company mergers slow down companies’ development processes. The top executives questioned the benefits of mergers and wondered whether they were driven by the financial markets and by financial consultants. They were the main beneficiaries of mergers – not the patients.

The winners, predicted the author of the report, will be companies that succeed in achieving a high organic growth rate, companies that sell or outsource in areas outside their own core areas and companies that focus on a small number of therapeutic areas and companies that focus their efforts on their own stores and customers. Companies will benefit from alliances with other companies and research groups, in-licensing, greater investment in research and development and strategic use of information technology.

The losers, on the other hand, would be companies with weak research portfolios but that chose to merge – those companies lose their focus and their rhythm, and therefore their competitiveness…

Article continued in links below

Links to whole article:
Click here to read the full article (in English)Translated from original Swedish by Opticom.
Click here to read the full article (in Swedish).



Download PDF

Opticom International Research freut sich, Sie als Hämophiliepatienten oder Eltern von Kindern mit Hämophilie einzuladen, an einer Diskussionsrunde, die wir im Auftrag eines Pharmaunternehmens das an der Behandlung für Hämophilie beteiligt ist, organisieren, teilzunehmen. Unser Kunde will eine Betreuungsleitung entwickeln für Personen mit Hämophilie und wir möchten Sie gerne einladen Ihre Bedürfnisse und Ideen in diesem Zusammenhang mit uns zu diskutieren.

• Möchten Sie an einer Diskussion teilnehmen und Ihre Meinung kundtun zu welche Art von Unterstützung Menschen mit Hämophilie benötigen und wie solche Leistungen entwickelt werden sollten?
• Stehen Sie für die Teilnahme an einer Gruppendiskussion, die ca. 2 Stunden dauert an einem Wochentag Abends zwischen dem 17. und 28. November in Köln durchgeführt wird, zur Verfügung?

Über die Fokusgruppe
Opticom International Research, ist eine unabhängiges, globales Beratungsunternehmen, spezialisiert auf Marktanalysen. Wir organisieren und führen die Gruppendiskussion, die objektiv sein wird und werden uns nicht auf die Krankheitsgeschichte oder private Angelegenheiten konzentrieren. Es wird etwas zu trinken und essen angeboten werden. Alle Teilnehmer kriegen eine Aufwandsentschädigung von 50 Euro.

Wenn Sie Interesse an der Teilnahme an einer Gruppendiskussion, die zur Entwicklung einer neuen Betreuungsleistung für Menschen mit Hämophilie beitragen können, haben, füllen Sie bitte das folgende Formular aus. Opticom wird sich so bald wie möglich bei Ihnen melden mit einer Einladung und weiteren Informationen.

Download PDF